PMID- 9334364
OWN - NLM
STAT- MEDLINE
DCOM- 19971121
LR  - 20210102
IS  - 0022-1007 (Print)
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 186
IP  - 8
DP  - 1997 Oct 20
TI  - Dendritic cells genetically modified with an adenovirus vector encoding the cDNA 
      for a model antigen induce protective and therapeutic antitumor immunity.
PG  - 1247-56
AB  - Dendritic cells (DCs) are potent antigen-presenting cells that play a critical 
      role in the initiation of antitumor immune responses. In this study, we show that 
      genetic modifications of a murine epidermis-derived DC line and primary bone 
      marrow-derived DCs to express a model antigen beta-galactosidase (betagal) can be 
      achieved through the use of a replication-deficient, recombinant adenovirus 
      vector, and that the modified DCs are capable of eliciting antigen-specific, 
      MHC-restricted CTL responses. Importantly, using a murine metastatic lung tumor 
      model with syngeneic colon carcinoma cells expressing betagal, we show that 
      immunization of mice with the genetically modified DC line or bone marrow DCs 
      confers potent protection against a lethal tumor challenge, as well as 
      suppression of preestablished tumors, resulting in a significant survival 
      advantage. We conclude that genetic modification of DCs to express antigens that 
      are also expressed in tumors can lead to antigen-specific, antitumor killer 
      cells, with a concomitant resistance to tumor challenge and a decrease in the 
      size of existing tumors.
FAU - Song, W
AU  - Song W
AD  - Division of Pulmonary and Critical Care Medicine, The New York Hospital-Cornell 
      Medical Center 10021, USA.
FAU - Kong, H L
AU  - Kong HL
FAU - Carpenter, H
AU  - Carpenter H
FAU - Torii, H
AU  - Torii H
FAU - Granstein, R
AU  - Granstein R
FAU - Rafii, S
AU  - Rafii S
FAU - Moore, M A
AU  - Moore MA
FAU - Crystal, R G
AU  - Crystal RG
LA  - eng
GR  - K08-HL 02926/HL/NHLBI NIH HHS/United States
GR  - R01-AR 40667/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
RN  - 0 (DNA, Complementary)
RN  - EC 3.2.1.23 (beta-Galactosidase)
SB  - IM
MH  - Adenocarcinoma/*immunology/prevention & control/therapy
MH  - Adenoviridae/*genetics/immunology
MH  - Animals
MH  - Bone Marrow Cells/immunology/virology
MH  - Bone Marrow Transplantation
MH  - Cell Line
MH  - Colonic Neoplasms/*immunology/prevention & control/therapy
MH  - DNA, Complementary/*immunology
MH  - Dendritic Cells/*immunology/*transplantation/virology
MH  - Gene Transfer Techniques
MH  - Genetic Vectors/immunology
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Lung Neoplasms/immunology/prevention & control/secondary
MH  - Lymphocyte Activation/genetics
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Models, Immunological
MH  - Neoplasm Transplantation
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - beta-Galactosidase/*immunology
PMC - PMC2199096
EDAT- 1997/10/23 00:00
MHDA- 1997/10/23 00:01
PMCR- 1998/04/20
CRDT- 1997/10/23 00:00
PHST- 1997/10/23 00:00 [pubmed]
PHST- 1997/10/23 00:01 [medline]
PHST- 1997/10/23 00:00 [entrez]
PHST- 1998/04/20 00:00 [pmc-release]
AID - 10.1084/jem.186.8.1247 [doi]
PST - ppublish
SO  - J Exp Med. 1997 Oct 20;186(8):1247-56. doi: 10.1084/jem.186.8.1247.